

Order

Technical

Tel

Fax

orders@abfrontier.com support@abfrontier.com +82-2-6933-6789 +82-2-6933-6780

http://www.abfrontier.com

rev. June 12, 2007

MONOCLONAL ANTI BODY

Anti-GPI-PLD(38A1)

(Anti-Glycosylphosphatidylinositol-specific phospholipase D)

Catalog No. LF-MA0156

Background GPI-PLD

(glycosylphosphatidylinositol-specific phospholipase D), a 815-amino acid protein, is expressed in numerous tissues and cells specifically cleaves GPI-anchored proteins. Liver has the highest level of GPI-PLD expression and is the primary organ contributing to GPI-PLD in the serum. GPI-PLD is abundant in serum in which it associates with apolipoproteins AI and AIV. Increased serum GPI-PLD is associated with insulin resistance and elevated serum triglycerides. Many surface proteins are attached to eukaryotic cell membranes via glycosylphosphatidylinositol (GPI) anchors that are covalently bound to the C-terminus of the protein and cleavage of the GPI moiety by GPI-PLD, only enzyme known that cleavage GPI anchor, may represent a means of regulating attachment of these proteins to the cell surface, or alternatively, their release into the extracellular environment.

Immunogen: Protein purified from Human

plasma

Host: Mouse

Clone number: 38A1


Isotype: IgG1, k **Size**: $100 \mu g (1 mg/ml)$


Composition: PBS containing 50% glycerol

Positive control: Human plasma

Storage: Store for 1 year at −20°C from date

of shipment





Immunoblot Analysis of human plasma protein

Lane 1: GPI-PLD protein isolated from human plasma

Lane 2: Human plasma

Applications:

ELISA

Western blotting (1:500)

Background Reference:

- 1) Chalasani N et al, J Clin Endocrinol Metab. 2006; vol.91(6): pp.2279-85.
- 2) MANN KJ et al, Biochem. J. 2004; vol.378: pp.641-
- 3) Gregory P et al, Bone. 2005; vol.37(2): pp.139-47.
- 4) Raikwar NS et al, Am J Physiol Endocrinol Metab. 2006; vol.290(3): pp.E463-70.

FOR RESEARCH PURPOSE ONLY NOT FOR DIAGNOSTIC OR THERAPEUTIC USE